NCT05881590

Hybrid Pulmonary Rehabilitation Study

Completed NA Last updated 17 July 2024

What this trial tests

NA trial testing Hybrid pulmonary rehabilitation in Respiratory Disease in 69 participants. Completed in 18 December 2023.

Timeline

4 May 2023

Primary endpoint
18 December 2023

18 December 2023

Quick facts

Lead sponsor	Anglia Ruskin University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	supportive care
Enrollment	69
Start date	4 May 2023
Primary completion	18 December 2023
Estimated completion	18 December 2023
Sites	1 location across United Kingdom

Drugs / interventions tested

• Hybrid pulmonary rehabilitation

Conditions studied

• Respiratory Disease — all drugs for Respiratory Disease →

Sponsor

Anglia Ruskin University

Who can join

18 and older, any sex, with Respiratory Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Pulmonary rehabilitation is an exercise and education programme that helps improve breathlessness and quality of life for people living with lung and breathing problems. It improves exercise levels and breathlessness and is a recommended treatment for people with lung diseases and symptoms. Standard pulmonary rehabilitation programmes involve individuals attending group classes at hospitals or community centres, twice a week for 8 weeks. These classes are supervised by physiotherapists. At the moment, there are long waiting times for pulmonary rehabilitation in the NHS.

Some patients may prefer more pulmonary rehabilitation based in their own home. This might be because they find it difficult to travel to classes. Some would like to do more home pulmonary rehabilitation in between supervised classes or continue pulmonary rehabilitation after the 8-week supervised programme. The blending between supervised classes and home pulmonary rehabilitation is known as HYBRID PULMONARY REHABILITATION. Hybrid pulmonary rehabilitation is not being provided routinely in the NHS, but the NHS would like to see it used more as it might help reduce waiting times and give patients more choice on how to access pulmonary rehabilitation.

The study will assess the feasibility of a larger study to provide strong evidence on patients' uptake and adherence to the hybrid programme, and the impact on patients' health outcomes and service delivery. The investigators will also look at what measures would be best to use in a larger study.

The study will recruit up to 100 patients. These individuals will be aged 18 years or older, have respiratory disease and a referral for pulmonary rehabilitation. Individuals with reasons why they cannot exercise will be excluded.

Participants will be provided with an application (App) that can be installed on a mobile phone. This App is called Active+me REMOTE and is made by a company called Aseptika Ltd (www.activ8rlives.com). Active+me REMOTE provides live online, video exercise classes; pre-recorded exercise classes; a walking programme; educational talks; and a care plan personalised for the user.

Data will be collected at the beginning and end of the hybrid pulmonary rehabilitation programme and will include routinely collected data as part of usual care. Additional data will be collected via the App and trial surveys. The investigators will ask staff and patients about the experiences of the new way of delivering rehabilitation and explore how cost effective it is.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

1. Acceptability of a digital pulmonary rehabilitation app as an adjunct or alternative to usual care for people with chronic lung diseases: A qualitative study of patients' views and experiences.
   Knight-Davidson P, Meshe OF, Jenkins TO, Edwards GD, et al · · 2025 · cited 2× · PMID 40803315 · DOI 10.1177/14799731251365632